Tepotinib
- Generic Name
- Tepotinib
- Brand Names
- Tepmetko
- Drug Type
- Small Molecule
- Chemical Formula
- C29H28N6O2
- CAS Number
- 1100598-32-0
- Unique Ingredient Identifier
- 1IJV77EI07
- Background
Tepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid tumors. It was originally developed in partnership between EMD Serono and the University of Texas M.D. Anderson Cancer Center in 2009 and has since been investigated in the treatment of neuroblastoma, gastric cancers, non-small cell lung cancer, and hepatocel...
- Indication
Tepotinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) who have mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer
- Associated Therapies
- -
Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)
- First Posted Date
- 2020-08-17
- Last Posted Date
- 2022-12-22
- Target Recruit Count
- 3
- Registration Number
- NCT04515394
- Locations
- 🇺🇸
University of California, Los Angeles (UCLA), Santa Monica, California, United States
🇺🇸Allegheny-Singer Research Institute, Pittsburgh, Pennsylvania, United States
🇺🇸Cancer Center of Kansas, Wichita, Kansas, United States
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
- Conditions
- Interventions
- First Posted Date
- 2019-05-07
- Last Posted Date
- 2024-12-11
- Target Recruit Count
- 140
- Registration Number
- NCT03940703
- Locations
- 🇺🇸
Community Health Network, Indianapolis, Indiana, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
🇨🇳The First Affiliated Hospital, Zhejiang University, Hangzhou, China
Effect of Tepotinib on PK of CYP3A Substrate Midazolam
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 12
- Registration Number
- NCT03628339
- Locations
- 🇩🇪
Nuvisan GmbH, Neu-Ulm, Germany
Tepotinib Hepatic Impairment Trial
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2024-08-12
- Target Recruit Count
- 18
- Registration Number
- NCT03546608
- Locations
- 🇺🇸
Qps Mra, Llc, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Effect of a Proton Pump Inhibitor on the PK of Tepotinib
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 12
- Registration Number
- NCT03531762
- Locations
- 🇩🇪
Nuvisan GmbH, Neu-Ulm, Germany
Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate
- First Posted Date
- 2018-04-10
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 20
- Registration Number
- NCT03492437
- Locations
- 🇩🇪
Nuvisan GmbH, Neu-Ulm, Germany
The Drug Rediscovery Protocol (DRUP Trial)
- Conditions
- Interventions
- Drug: PanitumumabDrug: OlaparibDrug: CrizotinibDrug: ErlotinibDrug: AlectinibDrug: Ipilimumab and nivolumabDrug: SunitinibDrug: Trastuzumab and Pertuzumab (combination treatment)Drug: Vemurafenib and Cobimetinib (combination treatment)Drug: NivolumabDrug: Dabrafenib and trametinibDrug: SelpercatinibDrug: TepotinibDrug: AbemaciclibDrug: ErdafitinibDrug: Atezolizumab and BevacizumabDrug: DacomitinibDrug: DabrafenibDrug: NilotinibDrug: TrametinibDrug: VismodegibDrug: RegorafenibDrug: AfatinibDrug: RibociclibDrug: LenvatinibDrug: PembrolizumabDrug: DurvalumabDrug: RucaparibDrug: AxitinibDrug: PalbociclibDrug: CabozantinibDrug: EntrectinibDrug: TalazoparibDrug: LorlatinibDrug: AlpelisibDrug: NiraparibDrug: Pemigatinib
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 1550
- Registration Number
- NCT02925234
- Locations
- 🇳🇱
Meander medisch centrum, Amersfoort, Netherlands
🇳🇱Netherlands Cancer Institute, Amsterdam, Netherlands
🇳🇱Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
- Conditions
- Interventions
- First Posted Date
- 2016-08-12
- Last Posted Date
- 2024-08-30
- Target Recruit Count
- 337
- Registration Number
- NCT02864992
- Locations
- 🇺🇸
Holy Cross Hospital Inc., Fort Lauderdale, Florida, United States
🇺🇸Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
🇺🇸Wenatchee Valley Hospital & Clinics - ATTN: Jay Johnson, Wenatchee, Washington, United States
c-Met Second-Line Hepatocellular Carcinoma
- First Posted Date
- 2014-04-16
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 66
- Registration Number
- NCT02115373
- Locations
- 🇩🇪
Please contact the Merck KGaA Communication Center located in, Darmstadt, Germany
Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2013-11-20
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 117
- Registration Number
- NCT01988493
- Locations
- 🇨🇳
Nanfang Hospital, Guangzhou, Guangdong, China
🇰🇷National Cancer Center, Goyang-si, Korea, Republic of
🇨🇳Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.